To resolve the apparent conflict between a lubricating glycoprotein, 'lubricin', as the active ingredient in synovial fluid (SF) and surface-active phospholipid (SAPL) present in SF (and adsorbed to articular cartilage) as the boundary lubricant reducing friction to such low physiological levels, lubricin was isolated from bovine SF following the original procedure of Swann et al. (Arthritis Rheum 1981;24:22-30). Analysis of the lipid extract by thin-layer chromatography and phosphorus determination demonstrated a phospholipid component of 11.1 +/- 1.7% (N = 5) which corresponds very closely to the 9.2-13.0% of lubricin which had hitherto remained unidentified and which has previously been shown to be transferable to the articular surface to impart lubrication. These results would appear to resolve any theoretical conflict in that lubricin is, indeed, an active ingredient within SF. Yet, as a large water-soluble molecule, it really functions as a carrier for the highly insoluble SAPL which it deposits on the articular surface as the oligolamellar layer visualized in previous studies. However, it is this deposited SAPL, rather than lubricin, which actually lubricates.

Previous studies have shown that synovial surfactant could have beneficial roles in the joint, especially as a very effective boundary lubricant capable of high load bearing. This study is aimed at further characterization and identification of the source. Known to be an important minor component of pulmonary surfactant, proteolipid has now been detected in appreciable quantities in bovine synovial fluid and bound to the articular surface. Using standard procedures to separate it from the major component [surface-active phospholipid (SAPL)] by column chromatography, proteolipid: phospholipid ratios were found to be comparable to those in the lung or in lamellar bodies (LBs). LBs are the unequivocal source of surfactant in the lung and we have confirmed an earlier study demonstrating their presence in Type B synoviocytes. Using a fixation procedure specifically designed to preserve the graphite-like structure of SAPL deposited as oligolamellar layers, or coiled as lamellar bodies, we were able to demonstrate these structures in equine joints adjacent to the Golgi apparatus associated with the secretory mechanism of the cell. These results indicate that proteolipid could be facilitating the deposition of the graphite-like surface lining of SAPL providing efficient boundary lubrication just as it promotes surfactant adsorption in the lung and in the formation of myelin. Any deficiency in synovial surfactant, compromising its roles in the joint, is discussed in relation to osteoarthritis and the possible administration of exogenous SAPL to the degenerating joint.

No abstract

CD97 is a dimeric glycoprotein belonging to the secretin receptor superfamily and is abundantly expressed in cells of hematopoietic origin. The aim of this study was to analyze the expression of the CD97 protein in thyroid carcinomas and the role of all-trans-retinoic acid (RA) in the regulation of CD97 protein in monolayer culture of the human follicular thyroid carcinoma cell line FTC-133. In normal thyroid tissue, no immunoreactivity of CD97 could be found, whereas in differentiated thyroid carcinomas, CD97 expression was either lacking or low. Undifferentiated anaplastic thyroid carcinomas revealed high CD97 expression. The expression of CD97 protein seems to be correlated to the postoperative histopathological classification staging. Approximately 50% of FTC-133 cells expressed the CD97 protein under basal culture conditions. No differences were found in the number of CD97-positive cells after TSH, forskolin, and insulin treatment compared to control values. Epidermal growth factor treatment led to an increase in CD97 immunostaining (up to 90%), whereas phorbol 12-myristate 13-acetate slightly decreased the immunoreactivity of CD97 (from 50% to 30%). Under basal conditions, RA treatment for 72 h led to a decrease in total cell number by 33% and in CD97-positive cells from 50% to 30%. TSH, forskolin, phorbol 12-myristate 13-acetate, and insulin showed no effect after 72-h pretreatment with RA, whereas epidermal growth factor treatment led to a slight increase in the number of the CD97-positive cells (from 30% to 40%) compared to the control value. These data suggest that CD97 expression may play an important role in the dedifferentiation of thyroid tumors, and RA might interfere with this process in thyroid carcinoma by suppressing the dedifferentiation marker CD97.

No abstract